Monograph Details
|
|
Gastrointestinal Tract
> Colorectal disorders
|
|
AMITIZA |
| Manufacturer |
|
Sucampo and Takeda |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
GI motility enhancer (chloride channel activator). |
| Generic Name |
|
Lubiprostone 8micrograms, 24micrograms; caps. |
| Indications |
|
Irritable bowel syndrome with constipation (IBS–C) in women. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Take with food and water. ≥18yrs: 8micrograms twice daily. |
| Contraindications |
|
History of mechanical GI obstruction. |
| Precautions |
|
Reevaluate periodically. Severe diarrhea: not recommended. Renal or hepatic impairment. Pregnancy (Cat.C): exclude pregnancy before starting; maintain effective contraception during therapy. Nursing mothers: not recommended. |
| Adverse Reactions |
|
Nausea, headache, diarrhea (suspend therapy if occurs), abdominal pain, abdominal distension, flatulence, dyspnea, vomiting, syncope, asthenia, others. |
| How Supplied |
8micrograms—60
24micrograms—60,100 |
|
|
|
|
